Medimynds

Company Overview

Snapshot

Founded in July 2025, Medimynds operates with 1–10 employees and is currently in the Pre-Funding stage. The company is developing its Admynds platform, a digital solution designed to enhance medication adherence.

Business overview

Medimynds develops Admynds, a digital platform that assists healthcare providers in conducting patient-tailored dialogues during medical encounters to improve medication adherence. The system customizes communication based on a patient's socio-psychological profile and integrates into provider workflows for both in-person and virtual care. The platform aims to improve adherence and related outcomes, reduce provider time spent on psychological assessment, and support value-based care goals for health systems within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Patient Engagement.

Company Intelligence Q&A

What is Medimynds' primary product?

Medimynds' primary product is Admynds, a digital platform designed to facilitate patient-tailored dialogues for healthcare providers to improve medication adherence.

When was Medimynds founded?

Medimynds was founded in July 2025.

What problem does Medimynds aim to solve?

Medimynds aims to improve medication adherence by providing healthcare providers with tools for personalized patient communication, thereby enhancing patient outcomes and supporting value-based care.

What is the current stage of Medimynds' product development?

Medimynds' product, Admynds, is currently in the Beta stage of development, indicating it is undergoing testing and refinement before a full public release.

In which sector does Medimynds primarily operate?

Medimynds primarily operates in the Health Tech & Life Sciences sector, with a focus on Digital Healthcare and Patient Engagement.